Multiple myeloma and anti-BCMA CAR-T therapy: a literature review

MD-Onco, Journal Year: 2025, Volume and Issue: 4(4), P. 53 - 64

Published: Jan. 15, 2025

Significant progress has been made in the treatment of multiple myeloma (MM), leading to improved clinical outcomes. However, despite success traditional methods such as surgery, radiotherapy, and chemotherapy, challenge fully curing patients with relapsed refractory MM remains pressing. A promising therapeutic approach is use chimeric antigen receptor T-cells (CAR-T), which demonstrated efficacy resistant B-cell malignancies actively being studied for MM. Special attention given maturation (BCMA) a potential target CAR-T therapy The objective analyze current state anti-BCMA ММ, covering aspects production, preclinical trials, well examining therapy-related toxicity relapses. Data analysis was conducted using specialized medical databases PubMed, Scopus, Web Science, Frontiers, Google Scholar from 1974 2024. article reviews latest achievements MM, advances production application BCMA CAR T-cells, along key challenges faced by this technology. data obtained confirm significant optimizing T-cell structures improving manufacturing processes, making more accessible use. Although early-phase trials show results, remain, insufficient response some patients. Optimization structure technologies may improve accessibility therapy, it direction future research.

Language: Английский

---

CAR-T cell therapy in the treatment of relapsed or refractory primary central nervous system lymphoma: recent advances and challenges

Leukemia & lymphoma/Leukemia and lymphoma, Journal Year: 2025, Volume and Issue: unknown, P. 1 - 13

Published: Feb. 3, 2025

Primary central nervous system lymphoma (PCNSL) is a rare and aggressive that isolated in the (CNS) or vitreoretinal space. High-dose methotrexate (HD-MTX)-based immunochemotherapy frontline for its treatment, with high early response rate. However, relapsed refractory (R/R) patients present numerous difficulties challenges clinical treatment. Chimeric antigen receptor (CAR)-T cells offer promising option treatment of hematologic malignancies, especially R/R B-cell multiple myeloma. Despite exclusion most PCNSL cases from pivotal CAR-T cell trials due to their specific tumor microenvironment (TME), available preclinical studies small cohorts suggest an overall acceptable safety profile remarkable anti-tumor effects. In this review, we will provide development process summarize research progress, limitations, future perspectives therapy PCNSL.

Language: Английский

---

STAT3 Signaling Pathway in Health and Disease

MedComm, Journal Year: 2025, Volume and Issue: 6(4)

Published: March 30, 2025

ABSTRACT Signal transducer and activator of transcription 3 (STAT3) is a critical factor involved in multiple physiological pathological processes. While STAT3 plays an essential role homeostasis, its persistent activation has been implicated the pathogenesis various diseases, particularly cancer, bone‐related autoimmune disorders, inflammatory cardiovascular neurodegenerative conditions. The interleukin‐6/Janus kinase (JAK)/STAT3 signaling axis central to activation, influencing tumor microenvironment remodeling, angiogenesis, immune evasion, therapy resistance. Despite extensive research, precise mechanisms underlying dysregulated disease progression remain incompletely understood, no United States Food Drug Administration (USFDA)‐approved direct inhibitors currently exist. This review provides comprehensive evaluation STAT3's health disease, emphasizing involvement cancer stem cell maintenance, metastasis, inflammation, drug We systematically discuss therapeutic strategies, including JAK (tofacitinib, ruxolitinib), Src Homology 2 domain (S3I‐201, STATTIC), antisense oligonucleotides (AZD9150), nanomedicine‐based delivery systems, which enhance specificity bioavailability while reducing toxicity. By integrating molecular mechanisms, pathology, emerging interventions, this fills knowledge gap STAT3‐targeted therapy. Our insights into crosstalk, epigenetic regulation, resistance offer foundation for developing next‐generation with greater clinical efficacy translational potential.

Language: Английский

---

Endosialin-directed CAR-T cell therapy: A promising approach for targeting triple-negative breast cancer

Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, Journal Year: 2025, Volume and Issue: unknown, P. 167852 - 167852

Published: May 1, 2025

Language: Английский

---

Engineered immune cell-based therapeutics for female reproductive tract cancers: Advances and future prospects

Journal of Reproductive Healthcare and Medicine, Journal Year: 2024, Volume and Issue: 5, P. 14 - 14

Published: Nov. 28, 2024

Cancers of the reproductive tract are one major causes deaths in women. The higher rate mortality among these cancers mainly due to late stage disease detection and resistance existing drugs. As research progresses, personalized medicine, which involves tailoring treatments unique characteristics each patient’s tumor, is expected play a significant role future. Engineered immune cells such as engineered dendritic cells, chimeric antigen receptor (CAR) T-cells, natural killer (NK) have emerged an innovative approach cure female (FRCs). These designed boost system’s ability identify remove cancer offering new therapeutic opportunities for patients with limited treatment options. present review highlights applicability various cell-based approaches treat FRCs. It also outlines potential combining nanoparticle-based engineering strategies further enhance effectiveness cell through improving delivery modulators. Overall, article promising improve outcomes

Language: Английский

---